Alan Ashworth

TL;DR: While gene fusions are present in some BRCA1-mutated breast cancers, they are infrequent and not recurrent, and private fusions may still be valuable as potential patient-specific biomarkers for diagnosis and treatment.

TL;DR: Modulation of the epigenetic state of T cell exhaustion can improve T cell responses in cancer immunotherapy and is demonstrated to improve anti-tumor immunity after adoptive cell therapy.

TL;DR: Using SNP data to impute alleles at classic HLA loci, an integrated analysis of HL risk within the HLA region in 582 early-onset HL cases and 4736 controls suggests that multiple independent loci within theHLA class II region contribute to the risk of developing early-ONSet HL.

TL;DR: A series of parallel, high-throughput small interfering RNA screens revealed a reliance of SS tumor cells upon the DNA damage response serine/threonine protein kinase ATR, and Combinations of cisplatin or PARP inhibitors enhanced the antitumor cell effect of ATRi, suggesting that either single-agent ATR i or combination therapy involving ATri might be further assessed as candidate approaches for SS treatment.

TL;DR: Male breast cancer accounts for approximately 1% of all breast cancer, and the relative risks associated with loci identified to date show subtype and, based on these data, gender specificity; additional studies of well-defined patient subgroups could provide further insight into the biological basis of breast cancer development.